Legal
The contents of this website:
(a) do not constitute a communication of an invitation or inducement to engage in investment activity for the purposes of Section 21 of the Financial Services and Markets Act 2000;
(b) do not constitute an offer or invitation to the public to acquire securities in Cyprotex or any solicitation of any offer or invitation to so acquire and no part of this website may be relied upon in relation to any such investment.
Cyprotex makes no representation and gives no warranty as to, and no responsibility or liability is accepted for, the accuracy or completeness of the contents of this website. Further, no responsibility is accepted by Cyprotex for any errors or mis-statements in or omissions from this website nor for any direct or consequential loss howsoever arising from any reliance on this website or its contents.
Genomic ADME - gADME™
Cyprotex's proprietary gADME™ system can alert you to genetic variations in drug metabolism, allowing for personalised doses, drug rescue and repositioning.
Learn more about gADME
In vitro Micronucleus Test
Cyprotex now offers the in vitro micronucleus test for genotoxicity assessment using an automated, high content screening method for improved detection and reliability.
Learn more about our in vitro MNT service
Drug Transporters
Cyprotex provides a full range of drug-transporter studies as recommended by the ITC white paper and EMA guidelines.
Learn more about transporters
By Dr. Katya Tsaioun, Chief Scientific Officer, Cyprotex
Wiley & Sons, March 2011
